Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of IMGC936-0901 in Advanced Solid Tumors
2021-002264-41Phase 2Active
- Sponsor
- ImmunoGen
- Start
- Sep 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of izeltabart tapatansine in advanced nonhematological malignancy and Non-small cell lung cancer (NS-NSCLC), sponsored by ImmunoGen. Primary endpoint: ORR. Started Sep 2021; status: active.
02
Drugs
izeltabart tapatansine
03
Conditions
advanced nonhematological malignancyNon-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2021-002264-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002264-41.